2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2016 Featured Talks » Immuno-Oncology: Rational combination therapy

Immuno-Oncology: Rational combination therapy

Chris Boshoff, MD, PhD

Chris Boshoff, MD, PhD, FMedSci
Vice President, Early Development
Translational and Immuno-Oncology

Chris Boshoff, M.D., Ph.D., FMedSci, is the Vice President for Early Development, Translational and Immuno-Oncology at Pfizer where he directs the strategies for early cancer drug development, and precision and immuno-oncology. He is a Co-Chair of the Oncology Research and Development Board, overseeing the early portfolio of cancer studies across the Pfizer Enterprise. Dr. Boshoff obtained his PhD from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London. Before joining Pfizer in 2013, he was the Director of the University College London (UCL) Cancer Institute (2007-2013). He has published more than 150 original articles covering cancer biology, tumor virology, and experimental cancer medicine.